

Prof. Durrant to present a plenary paper at SMI's 3rd Annual Cancer Vaccine conference in September

LONDON, LONDON, UNITED KINGDOM, May 23, 2014 /EINPresswire.com/ -- In recent weeks, Scancell plc have announced that Prof. Lindy Durrant, Joint CEO of the Company, will be presenting a paper entitled "Phase I/II trial of a novel antibody DNA immunotherapy, SCIB1 ImmunoBody which targets CD64, in the treatment of Melanoma" at SMI's 3rd Annual [Cancer Vaccines](#) conference, 15-16 September 2014, in London. The paper will describe interim results, as at December 2013, from the Company's ongoing Phase I/II trial. Of the 25 patients recruited at that time, 23 were treated with SCIB1 per protocol. Of these, 20 patients were considered to have shown an immune response* <http://www.scancell.co.uk/Apps/Content/News/?id=321>



A snap shot of those attending Cancer Vaccines 2014, sponsored by Scancell and Immudex include: Amal Therapeutics, Amgen, Cancer Vaccines Ltd, Curevac, DanDrit Biotech, GSK, Hybrid Systems, Immatics Biotechnologies GmbH, Immunicum, University Of Pennsylvania, University Of Southampton, University Of Tuebingen and Vaccinogen plus many more



We hope to reach out to cancer vaccine developers aiming at helping with elucidating the tumor-specific responses elicited by their therapeutic approach"

Immudex

A programme is available to download online at www.cancer-vaccineevent.com

About SMI Group

Established since 1993, the SMI Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and

Pharmaceutical industries.

We pride ourselves on having access to the worlds most forward thinking opinion leaders and

visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at <http://www.smi-online.co.uk>

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/206112782>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.